| A meta-analysis of GFR slope as a surrogate endpoint for kidney failure | 37330614 | | Journal | 2023 | 10.1038/s41591-023-02418-0 | HALT PKD, FSGS/FONT, FONT II | 22864, 23584 | Secondary Research |
| Acute treatment effects on GFR in randomized clinical trials of kidney disease progression. | 34862238 | PMC8819983 | Journal | 2022 | 10.1681/ASN.2021070948 | HALT PKD | 21181 | Secondary Research |
| Change in albuminuria and GFR slope as joint surrogate endpoints for kidney failure - Implications for phase 2 clinical trials in chronic kidney disease | 36918388 | | Journal | 2023 | 10.1681/ASN.0000000000000117 | HALT PKD | 21181 | Secondary Research |
| Development of a Clinical Trial Enrichment (CTE) Tool for Autosomal Dominant Polycystic Kidney Disease | | | Conference Presentation | 2023 | | HALT PKD, CRISP | 22905 | Secondary Research |
| Effects of Tolvaptan on Kidney Function Decline in Patients Aged >55 Years With Autosomal Dominant Polycystic Kidney Disease: Pooled Data Analysis | 37250503 | PMC10220412 | Journal | 2023 | 10.1016/j.xkme.2023.100639 | HALT PKD, CRISP | 21540 | Secondary Research |
| Impact of early glomerular filtration rate decline in
response to antihypertensive treatment on risk of
end-stage kidney disease and cardiovascular outcomes:
a systematic review and meta-analysis | 34930868 | | Journal | 2022 | 10.1097/HJH.0000000000003066 | HALT PKD | 23180 | Secondary Research |
| KIDNEY FUNCTION DECLINE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS: ASSESSMENT OF TOLVAPTAN'S REAL WORLD EFFECTIVENESS | | | Conference Presentation | 2023 | | HALT PKD, CRISP | 21540 | Secondary Research |
| POOLED DATA ANALYSIS OF THE EFFECT OF TOLVAPTAN IN PATIENTS AGED 18-35 YEARS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | 35570988 | PMC9091612 | Conference Presentation | 2023 | 10.1016/j.ekir.2022.02.009 | HALT PKD, CRISP | 21540 | Secondary Research |
